AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12072669 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with similar regimen of placebo drugs.
Number of subjects: 55
Study 12072669 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 55
Study 12072669 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 55
Study 9797418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day cefixime 400 mg
Number of subjects: 167
Study 9797418 — intervention group
Group type: COMPARATOR
Intervention: 10-day cefixime 400 mg
Number of subjects: 167
Study 7652141 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol of cooperation and communication between internist and general practitioner with psychiatric consultation
Number of subjects: 106
Study 7652141 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol restricted to cases with more severe psychiatric comorbidity
Number of subjects: 106
Study 2540896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene
Number of subjects: 200
Study 2540896 — intervention group
Group type: COMPARATOR
Intervention: Dexon
Number of subjects: 200
Study 101296 — intervention group
Group type: EXPERIMENTAL
Intervention: Short intensification with cytosine-arabinoside and cyclophosphamide after complete remission
Number of subjects: 465
Study 101296 — intervention group
Group type: COMPARATOR
Intervention: Weekly doses of 6-mercaptopurine and methotrexate
Number of subjects: 465
Study 101296 — intervention group
Group type: EXPERIMENTAL
Intervention: Further 3 month-doses of intrathecal methotrexate and dexamethasone
Number of subjects: 465
Study 101296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification, daily maintenance, and further intrathecal therapy
Number of subjects: 465
Study 101296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates at 36 months
Number of subjects: 465
Study 31456986 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of family members during EGD
Number of subjects: 96
Study 31456986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no family members present)
Number of subjects: 96
Study 29527478 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model using radiomic features extracted from MR images
Number of subjects: 272
Study 29527478 — intervention group
Group type: COMPARATOR
Intervention: Individual radiomic features
Number of subjects: 272
Study 27072971 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A 100 mL (P100 group)
Number of subjects: 200
Study 27072971 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A 250 mL (P250 group)
Number of subjects: 200
Study 27072971 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A 500 mL (P500 group)
Number of subjects: 200
Study 27072971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline 500 mL (N500 group)
Number of subjects: 200
Study 27072971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine 500 mL (G500 group)
Number of subjects: 200
Study 25518300 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 50
Study 25518300 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 50
Study 22266043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed in combination with cisplatin
Number of subjects: 2388
Study 22266043 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent pemetrexed
Number of subjects: 2388
Study 22266043 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine
Number of subjects: 2388
Study 22266043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2388
Study 20637149 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1‐0.3 mg/kg)
Number of subjects: 120
Study 20637149 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.3‐0.5 mg/kg)
Number of subjects: 120
Study 20637149 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (maintenance dose 1‐8 mg/kg per hour)
Number of subjects: 120
Study 20637149 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (maintenance dose 0.5‐1 mg/kg per hour)
Number of subjects: 120
Study 17970410 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI) as a feedback tool
Number of subjects: 0
Study 17970410 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI)
Number of subjects: 0
Study 15731556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 37
Study 15731556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12053548 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids for diffuse proliferative extracapillary forms or moderately severe NIgA with normal renal function
Number of subjects: 0
Study 9337359 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus (LLD) position
Number of subjects: 0
Study 9337359 — intervention group
Group type: COMPARATOR
Intervention: Kneeling (K) position
Number of subjects: 0
Study 7932136 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 x 6.0 mm ovoid PMMA lens
Number of subjects: 0
Study 7932136 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0 mm round PMMA lens
Number of subjects: 0
Study 7932136 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5 mm round PMMA lens
Number of subjects: 0
Study 7932136 — intervention group
Group type: COMPARATOR
Intervention: All IOL groups
Number of subjects: 0
Study 3283789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg IV)
Number of subjects: 0
Study 3283789 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg IV)
Number of subjects: 0
Study 3283789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 3283789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Diazepam
Number of subjects: 0
Study 28605148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Core Stability program (DCS)
Number of subjects: 31
Study 28605148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 27839852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioethanol CleanCook stoves
Number of subjects: 271
Study 27839852 — intervention group
Group type: COMPARATOR
Intervention: Firewood/Kerosene stove (Control)
Number of subjects: 271
Study 26181087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 micrograms every 3 hours for up to six doses)
Number of subjects: 130
Study 26181087 — intervention group
Group type: COMPARATOR
Intervention: Buccal misoprostol (400 micrograms every 3 hours for up to six doses)
Number of subjects: 130
Study 26181087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 130
Study 26181087 — intervention group
Group type: COMPARATOR
Intervention: Buccal misoprostol
Number of subjects: 130
Study 26181087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol and Buccal misoprostol
Number of subjects: 130
Study 23551925 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 18
Study 23551925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21348568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed guaiac‐based fecal occult blood tests (gFOBTs)
Number of subjects: 7053
Study 21348568 — intervention group
Group type: COMPARATOR
Intervention: Visit-based colorectal cancer screening (Control group 1)
Number of subjects: 7053
Study 21348568 — intervention group
Group type: COMPARATOR
Intervention: Visit-based colorectal cancer screening (Control group 2)
Number of subjects: 7053
Study 21348568 — intervention group
Group type: COMPARATOR
Intervention: Visit-based colorectal cancer screening (Control group 3)
Number of subjects: 7053
Study 18449422 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP administration
Number of subjects: 36
Study 16713541 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5-FU-based chemoradiotherapy
Number of subjects: 607
Study 16713541 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 607
Study 14517521 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.GG plus corticosteroids (G+S group)
Number of subjects: 32
Study 14517521 — intervention group
Group type: COMPARATOR
Intervention: i.v.GG alone (G group)
Number of subjects: 32
Study 10634736 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch screen system
Number of subjects: 875
Study 10634736 — intervention group
Group type: COMPARATOR
Intervention: Leaflet information only
Number of subjects: 875
Study 8959424 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 28
Study 8959424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (visual non-movement)
Number of subjects: 28
Study 7827632 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercises
Number of subjects: 14
Study 7827632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonweight-bearing exercises
Number of subjects: 14
Study 7827632 — intervention group
Group type: COMPARATOR
Intervention: Lachman's evaluation
Number of subjects: 14
Study 3277558 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (3.4 g, three doses per day)
Number of subjects: 26
Study 3277558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 26
Study 30267954 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with an anti-fat peer
Number of subjects: 146
Study 30267954 — intervention group
Group type: COMPARATOR
Intervention: Interaction with an unbiased peer
Number of subjects: 146
Study 28095881 — intervention group
Group type: EXPERIMENTAL
Intervention: High ferritin FCM
Number of subjects: 353
Study 28095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ferritin FCM
Number of subjects: 353
Study 28095881 — intervention group
Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 353
Study 24835412 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive rumination
Number of subjects: 0
Study 24835412 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study 24835412 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CTL)
Number of subjects: 0
Study 23158515 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS (0.8 g/100 ml)
Number of subjects: 92
Study 20850959 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg once daily (PM)
Number of subjects: 96
Study 20850959 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg once daily (AM)
Number of subjects: 96
Study 20850959 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg twice daily
Number of subjects: 96
Study 20850959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 16891005 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 27
Study 16891005 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty and stent implantation alone (Control)
Number of subjects: 27
Study 16258919 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise 3 times weekly for 4 months
Number of subjects: 45
Study 16258919 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 45
Study 12406669 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 micro g)
Number of subjects: 10
Study 12406669 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 micro g)
Number of subjects: 10
Study 12406669 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micro g)
Number of subjects: 10
Study 11247067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg administered daily for 12 to 24 weeks
Number of subjects: 310
Study 7972972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (8 mg four times daily)
Number of subjects: 29
Study 7972972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2732064 — intervention group
Group type: EXPERIMENTAL
Intervention: Know Your Body (KYB) program
Number of subjects: 1041
Study 2732064 — intervention group
Group type: EXPERIMENTAL
Intervention: Know Your Body (KYB) program (best teachers)
Number of subjects: 1041
Study 2732064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1041
Study 31909908 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARE predictive scale
Number of subjects: 902
Study 31286649 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable membranes (Ti-PTFE)
Number of subjects: 40
Study 31286649 — intervention group
Group type: COMPARATOR
Intervention: Resorbable membranes with titanium mesh (Collagen plus Ti-mesh)
Number of subjects: 40
Study 29246240 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma hs‐cTnI concentrations
Number of subjects: 87
Study 29246240 — intervention group
Group type: EXPERIMENTAL
Intervention: New LGE
Number of subjects: 87
Study 29246240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical peri‐operative type 5 myocardial infarction
Number of subjects: 87
Study 29246240 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of LGE
Number of subjects: 87
Study 29246240 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic humoral inflammatory biomarkers
Number of subjects: 87
Study 29246240 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO‐defined cellular myocardial inflammation
Number of subjects: 87
Study 26286548 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training (58 half-hour sessions over 12 weeks)
Number of subjects: 0
Study 26286548 — intervention group
Group type: COMPARATOR
Intervention: Mock training (active control group)
Number of subjects: 0
Study 26286548 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 26286548 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly (received the same training)
Number of subjects: 0
Study 21554710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation (40 g daily for 12 weeks)
Number of subjects: 9
Study 21554710 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran supplementation (40 g daily for 12 weeks)
Number of subjects: 9
Study 17909090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 60
Study 17909090 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 60
Study 17249841 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire
Number of subjects: 0
Study 17249841 — intervention group
Group type: EXPERIMENTAL
Intervention: Long questionnaire
Number of subjects: 0
Study 12839281 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwPHib vaccine
Number of subjects: 0
Study 12839281 — intervention group
Group type: COMPARATOR
Intervention: DTwP + Hib
Number of subjects: 0
Study 11125709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence Repetition test (SR)
Number of subjects: 0
Study 11125709 — intervention group
Group type: EXPERIMENTAL
Intervention: New normative data for SR
Number of subjects: 0
Study 11125709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical group performance
Number of subjects: 0
Study 11125709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity tests of SR
Number of subjects: 0
Study 9358531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal clindamycin (20 mg/kg body weight, four times per day)
Number of subjects: 100
Study 9358531 — intervention group
Group type: COMPARATOR
Intervention: Oral clindamycin (20 mg/kg body weight, three times per day)
Number of subjects: 100
Study 1544690 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening shift (1600-2400 hours)
Number of subjects: 6
Study 1544690 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shift (0000-0800 hours)
Number of subjects: 6
Study 1544690 — intervention group
Group type: COMPARATOR
Intervention: Day shift (0800-1600 hours)
Number of subjects: 6
Study 2580422 — intervention group
Group type: COMPARATOR
Intervention: Zimeldine
Number of subjects: 24
Study 2580422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alaproclate
Number of subjects: 24
Study 30527876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mimycx virtual games
Number of subjects: 79
Study 29530072 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT) alone (S1)
Number of subjects: 0
Study 29530072 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (CT) with extracorporeal hemoperfusion therapy (HCT) (S2)
Number of subjects: 0
Study 29530072 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study 27055193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet interventions (4 diet groups with varying macronutrient intakes)
Number of subjects: 768
Study 27055193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet interventions
Number of subjects: 768
Study 25304851 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cidofovir (gel, 10 g tube, applied for 6 weeks)
Number of subjects: 180
Study 25304851 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod (250 mg sachet, self-applied three times a week for a maximum of 24 weeks)
Number of subjects: 180
Study 25304851 — intervention group
Group type: COMPARATOR
Intervention: 1% cidofovir
Number of subjects: 180
Study 25304851 — intervention group
Group type: COMPARATOR
Intervention: 5% imiquimod
Number of subjects: 180
Study 25304851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 180
Study 22502844 — intervention group
Group type: EXPERIMENTAL
Intervention: Kata techniques training (exercise group, n=15)
Number of subjects: 30
Study 22502844 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group (n=15)
Number of subjects: 30
Study 19939985 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple RDA multivitamins
Number of subjects: 1129
Study 19939985 — intervention group
Group type: COMPARATOR
Intervention: Single RDA multivitamins
Number of subjects: 1129
Study 17852477 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry nutritional supplement
Number of subjects: 12
Study 17852477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17852477 — intervention group
Group type: COMPARATOR
Intervention: Blueberry nutritional supplement and Placebo
Number of subjects: 12
Study 15994013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile lubricant (KY-Jelly) and sterile razor debridement
Number of subjects: 20
Study 15994013 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 20
Study 15463813 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC C‐53 (prostaglandin E(1) associated with egg phosphatidylcholine liposomes) at doses of 0.15-1.8 microg/kg by 4 x 1-h infusions
Number of subjects: 20
Study 15463813 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC C‐53 (prostaglandin E(1) associated with egg phosphatidylcholine liposomes)
Number of subjects: 20
Study 15463813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10340731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pancreatitis patients (mild and severe)
Number of subjects: 56
Study 10340731 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 56
Study 10340731 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with electrocardiographic abnormalities
Number of subjects: 56
Study 8935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicitly informed subjects
Number of subjects: 0
Study 8935906 — intervention group
Group type: COMPARATOR
Intervention: Uninformed subjects
Number of subjects: 0
Study 8935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both informed and uninformed subjects
Number of subjects: 0
Study 2015155 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of L4 by physically constructing Tuffier's line
Number of subjects: 50
Study 6212554 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 100 mg
Number of subjects: 146
Study 6212554 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 146
Study 6212554 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 146
Study 6212554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 6212554 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 146
Study 30850837 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein intake (0.90 g · kg‐1 · d‐1)
Number of subjects: 1561
Study 30850837 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein intake
Number of subjects: 1561
Study 30850837 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein intake
Number of subjects: 1561
Study 28662466 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-contingent reward with informationally administered reward
Number of subjects: 84
Study 28662466 — intervention group
Group type: COMPARATOR
Intervention: Task-contingent reward with no feedback (Control)
Number of subjects: 84
Study 25800412 — intervention group
Group type: EXPERIMENTAL
Intervention: iGEL
Number of subjects: 38
Study 25800412 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA
Number of subjects: 38
Study 25800412 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS
Number of subjects: 38
Study 25800412 — intervention group
Group type: EXPERIMENTAL
Intervention: MCL
Number of subjects: 38
Study 24859205 — intervention group
Group type: EXPERIMENTAL
Intervention: IFL (irinotecan, fluorouracil, and leucovorin)
Number of subjects: 615
Study 24859205 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 615
Study 24859205 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 615
Study 22044486 — intervention group
Group type: EXPERIMENTAL
Intervention: Involving relatives in relapse prevention planning
Number of subjects: 52
Study 19716637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb strength training (12 weeks, 3 days per week)
Number of subjects: 27
Study 19716637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27